Coherus Biosciences (CHRS)
NASDAQ:CHRS
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.41Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook: the company has materially improved its balance sheet (>$250M divestiture proceeds and >90% debt reduction), demonstrated strong commercial momentum with LOQTORZI (113% y/y revenue growth) and compelling survival data, secured a strategic J&J collaboration, and expects multiple clinical readouts beginning mid-2026. Offsetting items include increased R&D spending (~49% Q4 y/y), remaining legacy liabilities and channel variability, and the multi-year path to achieve commercial scale (target $175M peak in 2028 and quarterly break-even thresholds). Overall, the positive developments (de-risked balance sheet, accelerating revenues, strategic partnerships, and promising clinical signals) outweigh the challenges reported.Company Guidance
Strategic Transformation and Balance Sheet Strengthening
Completed transition to an innovative oncology company, divested biosimilar franchise for $250 million, and reduced secured and convertible debt by over 90% from ~$480 million to $38.8 million at year-end 2025.
Strong LOQTORZI Commercial Momentum
LOQTORZI net revenue grew to $40.8 million for full-year 2025 versus $19.1 million in 2024, representing 113% year-over-year growth; Q4 net revenue was $12.4 million (11% growth over Q3) with quarter-over-quarter demand growth of 15.5%.
Compelling Long-Term Survival Data
Six-year overall survival data for LOQTORZI plus chemotherapy shows median ~65 months versus <36 months for chemo alone — approximately a 2.5-year (30+ month) survival advantage, supporting strong clinical differentiation and NCCN positioning.
Cash and Financing Position
Cash, cash equivalents and investments of $172.1 million at year-end 2025 plus a recent ~$50 million follow-on raise to support commercial expansion and pipeline investments.
Reduced Interest Expense and Improved Liquidity
Cash paid for interest fell to $9.9 million in 2025 versus $25.4 million in 2024, a savings of >$15 million following debt paydowns; earliest debt maturity extended to May 2029.
Operational Efficiency and Cost Discipline
Headcount reduced by ~35% (from ~228 to ~147) and Q4 SG&A from continuing operations decreased to $23.6 million from $29.6 million in Q4 2024 (down ~20%), reflecting ongoing cost control during transformation.
Promising Pipeline Data and Near-Term Readouts
Tagmokitug demonstrated selective depletion of CCR8+ tumor Tregs and a marked increase in CD8 T cells with an observed partial response in a 4th-line head & neck patient refractory to prior PD-1 therapy; casdozokitug (with Atezo/Bev) showed ORR 38% and CR 17% in first-line HCC (ASCO GI 2025). Multiple initial data readouts expected from mid-2026 onward.
Strategic Partnership Validation
Collaboration with Johnson & Johnson to study tagmokitug combined with pasritamig (a KLK2-targeting TCE) — validation of scientific approach and strategy to be Treg depleter of choice; potential to offset pivotal costs via ex-U.S. partnerships.
CHRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CHRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 09, 2026 | $1.93 | $1.95 | +1.04% |
Nov 06, 2025 | $1.49 | $1.34 | -10.07% |
Aug 07, 2025 | $0.88 | $0.82 | -7.13% |
May 12, 2025 | $1.02 | $0.82 | -19.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Coherus Biosciences (CHRS) report earnings?
Coherus Biosciences (CHRS) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Coherus Biosciences (CHRS) earnings time?
Coherus Biosciences (CHRS) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHRS EPS forecast?
CHRS EPS forecast for the fiscal quarter 2026 (Q1) is -0.26.